Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR)
- First Online:
- 322 Downloads
GSK-MMR (Priorix™ is a trivalent live attenuated measles, mumps and rubella (MMR) vaccine which contains the Schwarz measles, the RIT 4385 mumps (derived from the Jeryl Lynn mumps strain) and the Wistar RA 27/3 rubella strains.
GSK-MMR as a primary vaccination demonstrated high immunogenicity in clinical trials in >7500 infants aged 9–27 months, and was as immunogenic as Merck-MMR (MMR® II). However, antimumps seroconversion rates and geometric mean titres (GMTs) were significantly higher in infants receiving GSK-MMR compared with Berna-MMR (Triviraten™ recipients.
Coadministration of GSK-MMR with a varicella vaccine (Varilrix™ GSK-M-MR/V) did not significantly affect the immunogenicity of GSK-MMR.
A persistent immune response to GSK-MMR has been demonstrated in follow-up data from several randomised trials. GMTs for measles, mumps and rubella antibodies remained high in GSK-MMR recipients 1–2 years post-vaccination and were similar to those in Merck-MMR recipients.
The immunogenicity of GSK-MMR was high, and similar to that of Merck-MMR, when used as a second dose in children aged 4–6 or 11–12 years who had received a primary vaccination with Merck-MMR in their second year of life.
Although there are no protective efficacy data concerning the GSK-MMR vaccine to date, the rubella Wistar RA 27/3 rubella and Schwarz measles strains have well established protective efficacy; the new RIT 4385 mumps strain is expected to afford similar protection from mumps to that achieved with mumps vaccines that contain the Jeryl Lynn mumps strain (e.g. Merck-MMR).
GSK-MMR was well tolerated as a primary or secondary vaccination, and in most clinical studies comparing GSK-MMR with Merck-MMR as a primary vaccination in infants, GSK-MMR was associated with significantly fewer local adverse events (e.g. pain, swelling and redness). The incidence of local adverse events with GSK-MMR, GSK-MMR/V or Berna-MMR was similar. GSK-MMR and Merck-MMR were associated with similar rates of fever, rash and parotid gland swelling, but Berna-MMR was associated with a lower incidence of fever. In conclusion, GSK-MMR is a highly immunogenic MMR vaccine with good tolerability. In clinical trials, the immunogenicity of GSK-MMR was similar to that of Merck-MMR, and the mumps component was more effective at eliciting seroprotection than that of Berna-MMR. Furthermore, GSK-MMR causes fewer injection-site adverse events than Merck-MMR. As such, GSK-MMR is an attractive alternative for immunisation against measles, mumps and rubella.
The immunogenicity of GSK-MMR (Priorix™) has been evaluated as a primary vaccination in healthy infants aged 9–27 months and as a secondary vaccination in healthy children aged 4–6 or 11–12 years. All vaccinations consisted of a single subcutaneous injection into the upper arm; immunogenicity was evaluated 35–77 days post-vaccination.
GSK-MMR as a primary vaccination in infants was as immunogenic as Merck-MMR (MMR® H); 96.1–100%, 91.7–98.6% and 98.1–100% of GSK–MMR recipients seroconverted to antimeasles, antimumps and antirubella, compared with 91.5–100%, 93.6–97.9% and 97.9–100% of Merck-MMR recipients. Geometric mean antibody titres (GMTs) for measles, mumps and rubella antibodies were also similar in GSK-MMR or Merck-MMR recipients. Although antimeasles and antirubella seroconversion rates and GMTs were similar after vaccination with GSK-MMR or Berna-MMR (Triviraten™), antimumps seroconversion rates and GMTs were significantly higher in infants receiving GSK-MMR than in Berna-MMR recipients.
The immunogenicity of GSK-MMR as a primary vaccination was not significantly affected by coadministration with a varicella vaccine (Varilrix™; GSK-M-MR/V). An immune response to the measles, mumps and rubella components was seen in 96.1–100% of GSK-MMR recipients, compared with 91.9–100% in GSK-MMR/V recipients 60–70 days post-vaccination.
A persistent immune response to GSK-MMR was demonstrated in several 1- to 2-year follow-up studies. GMTs for measles, mumps and rubella antibodies remained high in GSK-MMR recipients 1–2 years post-vaccination and were similar to those in Merck-MMR recipients.
GSK-MMR showed similar immunogenicity to Merck-MMR when used as a second dose in children aged 4–6 or 11–12 years who had received a primary MMR vaccination in their second year of life. There were no significant between-group differences in immune response rates or GMTs in children initially (at the time of the second dose) seronegative to measles, mumps or rubella antibodies in both studies. Among seropositive children aged 11–12 years, post-second-dose GMTs of antimumps and antirubella were significantly higher in GSK-MMR than Merck-MMR recipients but antimeasles GMTs were significantly higher in Merck-MMR recipients. In the younger children who were initially seropositive, post-vaccination immune response rates and GMTs were similar between groups.
The rubella Wistar RA 27/3 and measles Schwarz strains have well established protective efficacy, and it is expected that protection from mumps with the RIT 4385 mumps strain will be similar to that achieved with other mumps vaccines that contain the Jeryl Lynn mumps strain (e.g. Merck-MMR), from which the RIT 4385 strain was derived.
In most clinical studies comparing GSK-MMR vaccine with Merck-MMR vaccine as a primary vaccination in infants, GSK-MMR was associated with significantly fewer local adverse events than Merck-MMR (e.g. injection-site pain, redness and swelling within 4 days). Indeed, the incidence of pain within the first 15 seconds or 30 minutes after vaccination in infants was significantly lower with GSK-MMR than Merck-MMR in the trials that reported such data. There were no significant between-group differences in the incidence of local adverse events within 3 days of the vaccination when GSK-MMR was compared with Berna-MMR or GSK-MMR/V. Severe pain was very rare, irrespective of which vaccine was administered.
The incidence of systemic adverse events (i.e. fever, rash and parotid gland swelling) after administration of GSK-MMR or Merck-MMR to infants was similar. Fever occurred most often during the second week post-vaccination. Berna-MMR, however, was associated with a significantly lower incidence of fever than GSK-MMR. The incidence of parotid gland swelling after administration of GSK-MMR, Merck-MMR or Berna-MMR was low (≤1.8%). In a pooled analysis, signs of suspected meningitis (e.g. febrile convulsions, vomiting, stiff neck, photophobia) were observed in three infants (0.1%) who received GSK-M-MR, and one recipient (0.1%) of Merck-MMR but were not considered related to the vaccines. Furthermore, there was no incidence of vaccine-related aseptic meningitis in a German 2-year post-marketing surveillance study during which time 1 575 936 doses of GSK-MMR were administered to children <15- years of age.
Coadministration of a varicella vaccine with GSK-MMR tended to increase the incidence of fever relative to GSK-MMR alone, and had no effect on or slightly increased the incidence of rash.
After administration of a second dose of GSK-MMR or Merck-MMR to children aged 4–6 or 11–12 years, significantly fewer GSK-MMR recipients experienced injection-site pain; the between-group incidences of redness and swelling were similar. The incidences of fever or rash were similar after administration of GSK-MMR or Merck-MMR as a second dose in children aged 4–6 or 11–12 years.
Dosage and Administration
GSK-MMR is indicated for active immunisation against measles, mumps and rubella for both the primary and secondary vaccination of children >12 months of age, although vaccination in younger infants (<12 months of age) may be indicated in some situations, such as in high risk areas. It can also be administered as a second dose in children, irrespective of which primary MMR vaccine was used.
The vaccine is available as a 0.5mL lyophilised mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps and Wistar RA 27/3 rubella virus strains, and should be administered subcutaneously into the upper arm; it should never be administered intravascularly. GSK-MMR does not contain porcine gelatin, thus allowing those with religious objections to pig products to be administered GSK-MMR.
GSK-MMR is contraindicated in individuals with acute severe febrile illness, impaired immune responses, systemic hypersensitivity to neomycin or any other component of the vaccine, and in pregnant women.
Unless the reactions are anaphylactic in nature, individuals with egg allergies can be considered for vaccination with GSK-MMR. However, caution should be used when vaccinating individuals with a history, or family history, of allergic disease or convulsions. As with all injectable vaccines, appropriate medical treatment (e.g. adrenaline [epinephrine]) should be available for use in the rare event of anaphylaxis.
- 2.World Health Organization. Global measles mortality reduction and regional elimination, 2000–2001. Wkly Epidemiol Rec 2002 Feb 15; 77(7): 50–5Google Scholar
- 3.World Health Organization. WHO-UNICEF joint statement on strategies to reduce measles mortality worldwide. Wkly Epidemiol Rec 2002 Jul 5; 77(27): 224–8Google Scholar
- 4.Koranyi K. Measles (rubeola). In: Rakel RE, Bope ET, editors. Conn’s current therapy. Philadelphia (PA): W.B. Saunders Company, 2002: 134–6Google Scholar
- 5.Gershon A. Mumps. In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 1147–8Google Scholar
- 6.Shope TC. Mumps. In: Rakel RE, Bope ET, editors. Conn’s current therapy. Philadelphia (PA): W.B. Saunders Company, 2002: 113–4Google Scholar
- 7.Gershon A. Rubella (German measles). In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 1145–7Google Scholar
- 12.GlaxoSmithKine Biologicals. Priorix: combined measles, mumps and rubella vaccine product monograph. Abingdon: TMG Heathcare Communications Ltd, 2002Google Scholar
- 13.Bernstein HH, Marchant C, Rathfon H, et al. Safety and immunogenicity of a new, live, attenuated combined measles, mumps and rubella vaccine in healthy U.S. children 12 to 18 months of age [abstract no. 1086]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, CA, 720Google Scholar
- 14.Crovari P, Gabutti G, Giammanco G, et al. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. Vaccine 2000 Jun 15; 18(25): 2796–803Google Scholar
- 15.Gatchalian S, Cordero-Yap L, Lu-Fong M, et al. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12–24 months of age. Southeast Asian J Trop Med Public Health 1999 Sep; 30(3): 511–7PubMedGoogle Scholar
- 16.Lee C-Y, Tang R-B, Huang F-Y, et al. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis 2002; 6(3): 202–9PubMedCrossRefGoogle Scholar
- 21.Arguedas A, Riccheimer R, Rocha C, et al. A randomized comparative study of a new measles, mumps and rubella (MMR) vaccine with a widely used MMR vaccine administered as a second dose at 4–6 years of age [abstract no. p-37 plus poster]. 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2000 May 3–5; Noordwijk, The NetherlandsGoogle Scholar
- 24.Ipp M, Cohen E, Goldbach M, et al. MMR vaccination at 12 months of age [abstract no. P30]. Proceedings of the 5th Canadian National Immunization Conference; 2002 Dec 1–3; Victoria, British Columbia, 143–4Google Scholar
- 25.Ipp M, Cohen E, Goldbach M, et al. Pain response to two licensed measles-mumps-rubella (MMR) vaccines in preschool children: a randomized comparative study [abstract no. 900]. Presented at the Annual Meeting of the Pediatric Academic Societies; 2002 May 4–7; Baltimore, MarylandGoogle Scholar
- 26.Wood C, Bourrillon A, Barberousse C, et al. Self-assessment of immediate post-vaccination pain after administration of Priorix versus MMRII as a second dose in 4- to 6-year-old children [abstract no. 7.00]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2003 Apr 9–11; Taormina, SicilyGoogle Scholar
- 28.GlaxoSmithKline. Priorix: summary of product characteristics [online]. Available from URL: http://Wuk.gsk.com [Accessed 2003 Apr 9]
- 29.British Medical Association and the Royal Pharmaceutical Society of Great Britain. MMR vaccine. British National Formulary. 43 ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002Google Scholar
- 30.Robert Koch-Institute. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut [online]. Available from URL: http://www.rki.de [Accessed 2003 Aug V]
- 31.World Health Organization. Progress in reducing global measles deaths. Wkly Epidemiol Rec 2003 May 23; 78(21): 184–7Google Scholar
- 33.Ciofi degli Atti ML, D’Argenio P, di Giorgio G, et al. Measles in Italy 2002: studies show correlation between vaccine coverage and incidence. Eurosurveillance Weekly 2002 Dec 5; 6(49): 5–8Google Scholar
- 35.World Health Organization. Vaccines, immunization and biologicals: immunization Profile — Germany [online]. Available from URL: http://www.who.int/vaccines/GlobalSummary/Immunization/ [Accessed 2003 Aug 7]
- 36.Impfausschusses des Obersten Sanitätsrates. Impfplan 2003 Osterreich [online]. Available from URL: http://www.gesundheit.bmsg.gv.at/ [Accessed 2003 Aug 7]
- 38.World Health Organization. Vaccines, immunization and biologicals: measles vaccine [online]. Available from URL: http://www.who.int/vaccines/en/measles.shtml [Accessed 2003 Apr10]
- 39.World Health Organization. Measles Technical Working Group: strategies for measles control and elimination [online]. Available from URL: http://www.who.int/vaccines-documents [Accessed 2003 Apr 11]
- 40.World Health Organization. Vaccines, immunization and biologicals: mumps vaccine [online]. Available from URL: http://www.who.int/vaccines/en/mumps.shtml [Accessed 2003 Apr10]
- 41.World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2001 Nov 9; 76(45): 346–55Google Scholar
- 42.World Health Organization. Vaccines, immunization and biologicals: rubella vaccine [online]. Available from URL: http://www.who.int/vaccines/en/rubella.shtml [Accessed 2003 Apr10]
- 45.Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998 May 22; 47(RR-8): 1–57PubMedGoogle Scholar
- 46.World Health Organization. Vaccines, Immunization and biologicals: adverse events following measles, mumps and rubella vaccine [online]. Available from URL: http://www.who.int/vaccines-diseases/safety/infobank/mmr.shtml [Accessed 2003 Apr 11]
- 48.Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. Vaccine 1998 May; 16 (8): 818–22Google Scholar
- 51.da Silveira CM, Kmetzsch CI, Mohrdieck R, et al. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol 2002 Oct; 31(5): 978–82PubMedCrossRefGoogle Scholar
- 53.Two MMR vaccines withdrawn after adverse reactions. Pharm J 1992 Sep 19; 249: 358Google Scholar
- 54.Shinefield HR, Black SB, Staehle BO, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J 2002 Jun; 21(6): 555–61PubMedCrossRefGoogle Scholar
- 62.Stratton K, Gable A, Shetty P, et al. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, 2001Google Scholar
- 74.Christie B. Scottish expert group finds no link between MMR and autism. BMJ 2002 May 11; 324: 2Google Scholar